Australia is facing a prolonged shortage of hormone replacement therapy (HRT) transdermal patches, with supply disruptions expected to continue until at least July 2026. The shortage is affecting patients managing menopause and perimenopause who rely on these vital treatments.

Pharmaceutical companies Sandoz and Juno Pharmaceuticals have advised the Therapeutic Goods Administration (TGA) of difficulties supplying both estradiol and combination estradiol/norethisterone (norethindrone) patches. The problem stems from global manufacturing constraints and an unexpected surge in demand.

In response, the TGA has fast-tracked approvals for several overseas-registered HRT patches to help meet patient needs. These alternative products will be subsidised under the Pharmaceutical Benefits Scheme (PBS), ensuring continued affordability and access. Pharmacists can order them through the Section 19A approvals database, where contact details for approved suppliers are listed.

To minimise disruption, pharmacists are now authorised to substitute approved alternatives without requiring a new prescription. This measure allows patients to continue treatment even if their regular brand is unavailable, though some may need to switch between brands during the supply shortage.

The TGA acknowledged the “concern and frustration” caused by the ongoing shortage and said it remains difficult to predict when Australian-registered patches will return to full supply. Patients are advised to consult their pharmacists for up-to-date information and guidance on obtaining their medication during this period.